SCHEDULE: Janus Henderson Divests Entire Vistagen Therapeutics Stake

Sentiment:

Ownership Disclosure Amendment 17 February 2026 12:35 PM

📋All filings for Vistagen Therapeutics, INC

Janus Henderson Group plc reports 0% beneficial ownership in Vistagen Therapeutics, Inc., signaling a complete divestment of its previous stake.

Worse than expectedJanus Henderson Group plc, a notable institutional investor, has reduced its beneficial ownership in Vistagen Therapeutics, Inc. to 0.0%, indicating a complete divestment of its previous stake.

Summary

Janus Henderson Group plc, a parent holding company, has filed an Amendment No. 1 to Schedule 13G for VISTAGEN THERAPEUTICS, INC.
As of December 31, 2025, Janus Henderson Group plc and its affiliated Asset Managers beneficially own 0.00 shares of Vistagen Therapeutics, Inc. Common Stock.
This represents 0.0% of the class of securities.
The filing indicates that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
The Asset Managers, including Janus Henderson Investors US LLC and others, exercise investment and/or voting discretion for their clients (Managed Portfolios) but disclaim ownership associated with dividends or sale proceeds.
None of the individual Managed Portfolios own more than five percent of Vistagen Therapeutics, Inc. common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal, as a complete divestment by a significant institutional investor typically reflects a diminished outlook or strategic shift away from the company.

Positives

Negatives

A significant institutional investor, Janus Henderson Group plc, has completely divested its beneficial ownership in Vistagen Therapeutics, Inc., reducing its stake to 0.0%.

Risks

Future Outlook

Management Comments

Kristin Mariani, Head of North America Compliance for Janus Henderson Group plc, certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a complete divestment by a major institutional investor like Janus Henderson Group plc can be perceived negatively by the market, potentially signaling a lack of confidence in Vistagen Therapeutics' future prospects or a reallocation of capital to other opportunities within the biotechnology sector.

Stakeholder Impact

Shareholders may interpret the complete divestment by Janus Henderson Group plc as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Date	Description
2022-12-09	Date Power of Attorney was executed by Janus Henderson Group plc.
2025-12-31	Date of event which requires filing of this statement (reporting period end date).
2026-02-17	Signature date of the Schedule 13G/A filing.

Recommendation

sell

The complete divestment by a major institutional investor like Janus Henderson Group plc, reducing its stake to 0%, suggests a lack of confidence in Vistagen Therapeutics' future performance. This action by a sophisticated investor often precedes or reflects negative developments, making a 'sell' recommendation prudent for existing holders and caution for potential investors.

Keywords

Vistagen Therapeutics, Janus Henderson, Schedule 13G, Institutional Ownership, Divestment, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.